Hikma Pharmaceuticals (HIK) PT Raised to GBX 1,074 at Jefferies Group

Hikma Pharmaceuticals (LON:HIK) had its price target raised by Jefferies Group from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) in a report published on Monday, December 4th. The firm currently has a hold rating on the stock.

A number of other equities research analysts have also recently commented on the stock. J P Morgan Chase & Co dropped their price objective on shares of Hikma Pharmaceuticals from GBX 1,500 ($20.19) to GBX 1,250 ($16.82) and set a neutral rating on the stock in a research note on Friday, October 6th. Numis Securities reiterated an add rating and set a GBX 1,560 ($21.00) target price on shares of Hikma Pharmaceuticals in a research report on Thursday, August 17th. Stifel Nicolaus lowered Hikma Pharmaceuticals to a hold rating and decreased their target price for the company from GBX 2,300 ($30.96) to GBX 1,320 ($17.77) in a research report on Tuesday, August 29th. Peel Hunt reiterated a hold rating and set a GBX 1,390 ($18.71) target price on shares of Hikma Pharmaceuticals in a research report on Wednesday, November 15th. Finally, Morgan Stanley reiterated an equal weight rating and set a GBX 1,100 ($14.80) target price on shares of Hikma Pharmaceuticals in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of GBX 1,188.90 ($16.00).

Hikma Pharmaceuticals (LON HIK) opened at GBX 1,069 ($14.39) on Monday. Hikma Pharmaceuticals has a fifty-two week low of GBX 906.50 ($12.20) and a fifty-two week high of GBX 2,346 ($31.57).

WARNING: “Hikma Pharmaceuticals (HIK) PT Raised to GBX 1,074 at Jefferies Group” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://ledgergazette.com/2017/12/13/hikma-pharmaceuticals-hik-pt-raised-to-gbx-1074-at-jefferies-group.html.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply